Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project.

The recent approval of PARP inhibitors for the treatment of metastatic -castration-resistant prostate cancer (mCRPC) patients with BRCA mutations firstly introduced the possibility of proposing a targeted treatment in this disease. However, the availability of this therapeutic option raises a number of questions concerning the management of prostate cancer in everyday clinical practice: the timing and method of detecting BRCA mutations, the therapeutic implications of the detection, and the screening of the members of the family of a prostate cancer patient with a BRCA alteration. These challenging issues led the Italian Society for Uro-Oncology (SIUrO) to organise a Consensus Conference aimed to develop suggestions capable of supporting clinicians managing prostate cancer patients. The present paper described the development of the statements discussed during the consensus, which involved all of the most important Italian scientific societies engaged in the multi-disciplinary and multi-professional management of the disease.

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Alberto Lapini has received fees or honoraria for acting as an advisor to Medac, Bayer, MSD and Janssen, Orazio Caffo has received fees or honoraria for acting as speaker or as an advisor to AAA, Astellas, Astra Zeneca, Bayer, Ipsen, Janssen, MSD, Pfizer, Giario Natale Conti has received fees or honoraria for acting as an advisor to Janssen, Astellas, Bayer, Recordati, MSD, Astrazeneca and Ipsen, Giovanni Luigi Pappagallo has received fees or honoraria for acting as an advisor to AAA, Astellas, Astrazeneca, Janssen, Marzia Del Re has received fees from Astellas, AstraZeneca, Celgene, Novartis, Pfizer, BioRad, Janssen, Sanofi-Aventis, Roche, MSD, Lilly and Ipsen; and honoraria for acting as an advisor to Astra Zeneca, MSD, Ipsen, Janssen, Sanofi-Aventis, and Amgen, Francesca Castiglione has received fees from AstraZeneca, Novartis, Roche, MSD, GSK, and honoraria for acting as an advisor to Astra Zeneca, MSD, and Amgen, Matteo Brunelli has received fees from MSD, Janssen, Genactis, NTP, Oncotech, Roberto Iacovelli has received fees or honoraria for acting as an advisor to Astellas, BMS, EISAI, IPSEN, Janssen, MSD, Novartis, Pfizer, Sanofi. Consultant for Astellas, EISAI, MSD, Pfizer, Ugo De Giorgi received honoraria for advisory boards or speaker fees for Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Roche, Novartis, Clovis, GSK, AstraZeneca, institutional research grants from AstraZeneca, Sanofi and Roche, Sergio Bracarda has received fees or honoraria for acting as an advisor from or steering committee member from AAA, Astellas, AstraZeneca, Bayer, BMS, Janssen, Ipsen, Merck, MSD, Pfizer, Roche, Sanofi. The other authors did not have conflicts of interest to be declared.